Table 1.
Dual-mobility (n = 150) | Unipolar (n = 166) | Mean/Risk differenceb(95% CI) | p-value | |
---|---|---|---|---|
Mean age (SD) | 73 (11.1) | 65 (15.2) | −7.9 (−11 to −4.9) | < 0.001 |
Mean BMI (SD) | 26 (5.8) | 26 (5.2) | −0.2 (−1.4 to 1.0) | 0.8 |
Mean operating time (SD), min | 152 (60) | 185 (69) | 33 (19 to 48) | < 0.001 |
Women (%) | 84 (56) | 76 (46) | 10 (−0.7 to 21) | 0.07 |
BMI ≥30 (%) | 38 (25) | 39 (24) | 1.8 (−7.7 to 11) | 0.7 |
Smoking statusc(%) | ||||
Ever-smoker | 58 (46) | 59 (52) | −6.5 (−19 to 6.1) | 0.3 |
Never-smoker | 69 (54) | 54 (48) | ||
ASA score (%) | ||||
1–2 | 96 (64) | 116 (70) | −5.9 (−16 to 4.5) | 0.3 |
3–4 | 54 (36) | 50 (30) | ||
Diabetes (%) | 26 (17) | 19 (11) | 5.9 (−1.9 to 14) | 0.1 |
Previous THA revision (%) | 38 (25) | 36 (22) | 6.7 (−5.7 to 13) | 0.4 |
Surgical approach (%) | ||||
With osteotomy | 33 (22) | 48 (29) | −6.9 (−17 to 2.7) | 0.2 |
Without osteotomy | 117 (78) | 118 (71) | ||
Posterior | 68 (46) | 43 (26) | ||
Anterior Hueter | 15 (10) | 14 (8.4) | ||
Antero-lateral | 34 (23) | 61 (37) | ||
Indication for revision (%) | ||||
Aseptic loosening | 51 (34) | 76 (46) | −12 (−23 to −1.1) | 0.03 |
Dislocation | 41 (27) | 17 (10) | 17 (8.6 to 26) | < 0.001 |
Infection | 22 (15) | 26 (16) | −1.0 (−8.9 to 6.9) | 0.8 |
Pain/impingement | 4 (2.7) | 19 (11) | −8.8 (−14 to −3.3) | 0.003 |
Polyethylene wear | 5 (3.3) | 5 (3.0) | 0.3 (−3.6 to 4.2) | 0.9 |
Adverse local tissue reaction | 7 (4.7) | 7 (4.2) | 0.5 (−4.1 to 5) | 0.9 |
Periprosthetic fracture | 17 (11) | 11 (6.6) | 4.7 (−1.6 to 11) | 0.1 |
Other | 3 (2.0) | 5 (3.0) | −1.0 (−4.4 to 2.4) | 0.6 |
Head size (%) | ||||
≤ 32 mm | 150 (100) | 114 (69) | 31 (24 to 38) | < 0.001 |
> 32 mm | – | 52 (31.3) | ||
Acetabular reinforce-ment ring (%) | 53 (35) | 77 (46) | −11 (−22 to −0.3) | 0.05 |
Percentages calculated on total no. of patients with information available.
Age, BMI, and operating time is Mean difference, the rest is Risk difference
Information on smoking status missing for 23 patients in group 1 and for 53 patients in group 2.